VWF/FVIII products
PreclinicalSmall molecule
VWF/FVIII products is one of 9 small molecule programs targeting Von Willebrand disease. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Von Willebrand Disease
#DrugCompanyPhaseTrials
1Advate
TakedaPhase 3
Vonicog Alfa
TakedaPhase 3
Antihemophilic Factor (recombinant)
TakedaPhase 3
VGA039
VVega Therapeutics, Inc
Phase 3
BT200
BBand Therapeutics
Phase 2
Recombinant Interferon Alfa 2a
RochePreclinical
Activated Prothrombin Complex Concentrate
RochePreclinical
Von Willebrand Factor Concentrates
RochePreclinical
VWF/FVIII products
SSkane University Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VWF/FVIII products. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSkane University Hospital